Randall Morris
Academic Appointments
- Emeritus Faculty, Acad Council, Cardiothoracic Surgery
Key Documents
Contact Information
- Academic Offices
Personal Information Email Tel (650) 723-5771
Professional Overview
Graduate & Fellowship Program Affiliations
Scientific Focus
Current Research Interests
1. Discovery, preclinical and clinical development of novel immunosuppressive molecules for use in cell and organ transplantation and autoimmune disease:
a. Direct inhibitors of calcineurin based on rational drug design derived from computational chemistry of cocrystallization of drug-enzyme complexes;
b. Competitive inhibitors of purine biosynthesis;
c. Inhibitors of pyrimidine and purine biosynthesis;
d. Tyrosine kinase inhibitors;
e. Inhibitors of cell cycle progression (rapamycin);
f. Inhibitors of T-cell specific NFkB and AP-1 transcription;
g. Anti-CD11a monoclonal antibodies;
h. Relationship between immunosuppressive drug mechanisms and antigen-stimulated T and B cell apoptosis.
2. Molecular mechanisms of immunosuppressive drug action in vitro and in vivo.
3. Relationship among dose, blood level and pharmacodynamic effects of immunosuppressive drugs in animals and humans.
4. Models, pathogenesis and treatment of chronic organ rejection.
5. Prevention and treatment of acute and chronic GvH in animals and humans.
6. Pharmacologic control of acute and chronic xenograft rejection.
7. Prevention of restenosis after balloon angioplasty.
Publications
- Prolongation of heart allograft survival by anti-LFA-1 monoclonal antibody monotherapy: mechanisms of induction of antigen-specific unresponsiveness. Transplantation.
- Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med. 2002; (3): 295-301
- Emerging therapies for autoimmune diseases. Nove. Therapeutic Agents for the Treatment of Autoimmune Diseases. New York: Marcel Decker,. 1996
- New immunosuppressive drugs. Transplantation of the Liver. W.B. Saunders. 1996
- Leflunomide prolongs pulmonary allograft and xenograft survival. J Heart Lung Transplant. 1995 Nov-Dec; (6 Pt 1): 1136-44
- Mechanism of the antiproliferative action of leflunomide: A771726, the active metabolite of leflunomide, does not block T cell receptor-mediated signal transductic but its antiproliferative... J. Heart Lung Transp.. 1995; (14): 1016-1030
Help